Hubungan Kadar Serum Ferritin Terhadap Gangguan Pertumbuhan Pada Anak Penderita Talasemia Beta Mayor
DAFTAR PUSTAKA
1. Weatherall DJ, Clegg JB. The ß- thalassaemias Dalam: Weatherall DJ, Clegg JB,
penyunting. The thalassaemia syndrome. Edisi ke 4. London: Blackwell science;
2001. h.287-356.
2. Galanello R, Origa R.Beta-thalasssemia. Orphanet J of
Rare Disease. 2010;
5:11-5.
3. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of
thalassemia. Blood J. 1997; 89:739-61.
4. Najafipour F, Aliashgarjadeh A, Niafar M, Mobaseri M, Agamohamadzadeh N,
Sorkhabi RS. Evaluation of glucose metabolisme, thyroid function, growth and
development pattern and calcium stastus in patients with thalassemia major.
Medwel J. 2008;3:867-73.
5. Hamidah A, Rahmah R, Azmi T, Aziz J, Jamal R. Short stature and truncal
shortening in transfusion dependent thalassemia patients: result from a
thalassemia center in Malaysia. Shouteast Asian J. 2001;32:625-30.
6. Moayeri H, Oloomi Z. Prevalence of growth and puberty failure with respect to
growth hormone and gonadotropin secretion in beta-thalassemia major. Arc
Iranian. 2006;9:329-34.
7. Bhala AK, Marwaha RK, Kaur H. Longitudinal growth attainments of transfusion
dependent ß-thalassemia children. Mankin quarterly. 2008;48:484-93.
8. Saxena A. Growth retardation in thalassemia major patients. Int J Hum Genet.
2003; 237-46.
9. Kyriakou A, Skordis N. Thalassemia and aberration of growth and puberty. Medit
J Hemat Infec Dis. 2009;4:1-8.
10. Made A, Ketut A. Profil pertumbuhan, hemoglobin pre-transfusi, kadar feritin,
dan usia tulang anak pada thalassemia mayor. Sari Pediatri. 2011;13:299-304.
31
11. Grimberg A, Leon DD. Disorders of growth. Dalam: Mosang T, penyunting.
Pediatric Endocrinology. Edisi I. Philadelphia: Elsevier Mosby; 2005. h.127-67.
12. Batubara J, Susanto R, Cahyono HA. Pertumbuhan dan gangguan pertumbuhan.
Dalam: Batubara J, Trijaya B, Pulungan AB, penyunting. Buku ajar endokrinologi
anak. Edisi I. Jakarta: Ikatan Dokter Anak Indonesia; 2010. h.19-41.
13. Patel L, Clayton PE. Normal and disordered growth. Dalam: Brook CGD, Clyton
PE, Brown RS, Savage MO, penyunting. Clinical Pediatric Endocrinology. Edisi
ke-5. Massachusette: Blackwell; 2005. h.90-111.
14. Dubey AP, Parakh A, Dublish S. Current trends of the management of beta
thalassemia. Ind J Pediatr. 2008;7:739-43.
15. Cappellini MD, Congenite CA, Cohlen A, Piga A, Porter J. Guideline for the
clinical management of thalassemia. Edisi ke-2 revisi. Cyprus: Thalassemia
International Federation; 2011. h.64-70.
16. Ibrahim
HM, Ayob Y, Mahayiddin AA, Sathar J, Musa Z, Bakri R, dkk.
Management of transfusion dependent thalassaemia. Malaysia:Ministry of Health
Malaysia; 2009.h.1-84.
17. Skordis N. Endocrine investigation and follow up in thalassemia: times for
specific guimLines. Thalassemia reports. 2011;1:1-16.
18. Sanctis V, Urso, Scialpi, Mangiagli . Endocrine complications in ß-thalassemia
major. Dalam: Maggio A, Hoffbrand AV, penyunting. Clinical aspects and
therapy of haemoglobinopathies. Italy: Proprieta letteraria riservata; 2004.h.293310.
19. Faranoush M, Rahiminejad MS, karamizadeh Z, Ghorbani R, Owji SM. Zinc
supplementation effect linear growth in transfusion dependent ß thalassemia.
IJBC. 2008;1:29-32.
20. Prabhu R, Prabhu V, Prabhu RS. Kelebihan besi in beta thalassemia –a revew. J
Biosci Tech. 2009;1;20-31.
21. Barton JC, Edwards CQ, Phatak PD, Britton RS, Bacon BR. Handbook of iron
overload. Edisi ke-1. New York: Cambridge university Press; 2010.h.233-41.
32
22. Mehvar A, Azarkeivan A, Faranoush M, Mehvar N, Saberinedjhad J, Ghorbani R.
Endocrinophaties with ransfution dependent betha thalassemia. Pediatr
Hem
Onc. 2008; 25:187-94.
23. Shamshirzas AA, Bekheirnia MR, Kamgar M, Pourzahedgilani N, Bouzari N,
Habibzadeh M, dkk. Metabolic and endocrinologic complications in betathalassemia major: a multicenter study in Taheran. BMC Endocrine Disorders.
2003; 3:1-6.
24. Khan FUR, Khan MH, Ayub T, Shah SH. Frekuency of complications in beta
thalassemia major in D.I. Khan. Biomedica. 2007; 23:31-3.
25. Soliman AT, Khalafallah H, Ashour R. Growth and factors affecting it in
thalassemia major. Hemoglobin. 2009; 33:116-26.
26. Low LCK. Growth of children with ß-thalassemia major. Indian J Ped. 2005;
72:159-63.
27. Paulev PE, Calleja GZ. Other hormones and disorders. Dalam : Paulev PE,
Calleja GZ, penyunting. New human fisiology. Edisi ke-2. Copenhagen Denmark.
Elsevier; 2010.h.251-3.
28. Karamifar H, Amirhakimi GH. Linier growth deficiency in ß-thalassemia patiens:
is it growth hormone dependent? IJMS. 2002; 27:47-50.
29. Fica S, Albu A, Vladareanu F, Barbu C, Bunghez R, Nitu L, dkk. Endocrine
disorders in ß-thalassemia major: cross sectional data. Act Endocr. 2005; 1:20112.
30. Roth C, Perkum A, Bartz M, Jarry H, Eber S, Lakomek M. Short stature and
failure of pubertal development in thalassemia major; evidence for hypothalamic
neurosecretory disfuncion of growth hormone secretion and defective pituitary
gonadotropin secretion. Eur J pediatr. 1997; 156:777-83.
31. Vogiatzi MA, Macklin EA, Tractenberg FL, fung EB, Cheung AM, vichinscy E.
Differences in the prevalence of growth, endocrine and vitamin D abnormalities
among the various thalassemia syndromes in North America. British J of
Haematology. 2009; 146:546-56.
33
32. Reiter EO, D’Ercole AJ. Disorders of anterior pituitary gland, hypothalamus and
growth. Dalam: Rudolf AM, Hotcler MK, Lister G, Siegel NJ, penyunting.
Rudolf’s Pediatric. Edisi ke-23. California: McGraw-Hill; 2003: h.2002.
33. Rindang C, batubara JL, Amalia P, Satari H. Some aspects of thyroid dysfunction
in thalassemia major patients with severe iron chelathing. Paediatr indones. 2011;
51:67-72.
34. Eshragi P, Tamaddoni A, Zarifi K, Mohammadhasani A, Aminzadeh M. Thyroid
function in major thalassemia patients: is it related to height and chelation
therapy? Casp J Inern Med. 2011; 2:189-93.
35. Angelucci E, Barosi G, Camaschella C, Cappelini DM, Cazzola , Galanello R.
Italian society of hematology practice guidelines for the management of kelebihan
besi in thalassemia major and related disorders. Haematologica. 2008; 93(5):74152.
36. Sayani F, Warner M, Wu J, Rieger DW, Humphreys K, Odame I. GuimLines for
the clinical care of patient with thalassemia in Canada. Thalassemia foundation of
Canada.Toronto. 2009:15-38.
37. Nabavizadeh SH, Anushiravani A, Haghbin S. Evaluation of growth parameters
in patients with thalassemia major. Hematology. 2007; 12(5):445-7.
38. Ware HM, Kwiatkowski JL. Evaluation and treatment of transfusional iron
overload in children. Pediatr Clin N Am. 2013;1393-1406.
39. Au WY, Li CF, Fang JP, Chen GF, Sun X, Li CG, dkk. Assesment of iron
overload in very young children with limited thalassemia care resources in South
China. Hemoglobin. 2014; 38(2):119-26.
40. Theil EC. Ferritin: at the crossroads of iron and oxygen metabolism. Blood. 1999;
94:3205-311.
41. Belhoul KM, Bakir ML, Saned MS, Kadhim AM, Musallam KM, Taher AT.
Serum ferritin levels and endocrinopathy in medically treated patients with β
thalassemia major. Ann Hematol. 2012; 91:1107-14.
34
1. Weatherall DJ, Clegg JB. The ß- thalassaemias Dalam: Weatherall DJ, Clegg JB,
penyunting. The thalassaemia syndrome. Edisi ke 4. London: Blackwell science;
2001. h.287-356.
2. Galanello R, Origa R.Beta-thalasssemia. Orphanet J of
Rare Disease. 2010;
5:11-5.
3. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of
thalassemia. Blood J. 1997; 89:739-61.
4. Najafipour F, Aliashgarjadeh A, Niafar M, Mobaseri M, Agamohamadzadeh N,
Sorkhabi RS. Evaluation of glucose metabolisme, thyroid function, growth and
development pattern and calcium stastus in patients with thalassemia major.
Medwel J. 2008;3:867-73.
5. Hamidah A, Rahmah R, Azmi T, Aziz J, Jamal R. Short stature and truncal
shortening in transfusion dependent thalassemia patients: result from a
thalassemia center in Malaysia. Shouteast Asian J. 2001;32:625-30.
6. Moayeri H, Oloomi Z. Prevalence of growth and puberty failure with respect to
growth hormone and gonadotropin secretion in beta-thalassemia major. Arc
Iranian. 2006;9:329-34.
7. Bhala AK, Marwaha RK, Kaur H. Longitudinal growth attainments of transfusion
dependent ß-thalassemia children. Mankin quarterly. 2008;48:484-93.
8. Saxena A. Growth retardation in thalassemia major patients. Int J Hum Genet.
2003; 237-46.
9. Kyriakou A, Skordis N. Thalassemia and aberration of growth and puberty. Medit
J Hemat Infec Dis. 2009;4:1-8.
10. Made A, Ketut A. Profil pertumbuhan, hemoglobin pre-transfusi, kadar feritin,
dan usia tulang anak pada thalassemia mayor. Sari Pediatri. 2011;13:299-304.
31
11. Grimberg A, Leon DD. Disorders of growth. Dalam: Mosang T, penyunting.
Pediatric Endocrinology. Edisi I. Philadelphia: Elsevier Mosby; 2005. h.127-67.
12. Batubara J, Susanto R, Cahyono HA. Pertumbuhan dan gangguan pertumbuhan.
Dalam: Batubara J, Trijaya B, Pulungan AB, penyunting. Buku ajar endokrinologi
anak. Edisi I. Jakarta: Ikatan Dokter Anak Indonesia; 2010. h.19-41.
13. Patel L, Clayton PE. Normal and disordered growth. Dalam: Brook CGD, Clyton
PE, Brown RS, Savage MO, penyunting. Clinical Pediatric Endocrinology. Edisi
ke-5. Massachusette: Blackwell; 2005. h.90-111.
14. Dubey AP, Parakh A, Dublish S. Current trends of the management of beta
thalassemia. Ind J Pediatr. 2008;7:739-43.
15. Cappellini MD, Congenite CA, Cohlen A, Piga A, Porter J. Guideline for the
clinical management of thalassemia. Edisi ke-2 revisi. Cyprus: Thalassemia
International Federation; 2011. h.64-70.
16. Ibrahim
HM, Ayob Y, Mahayiddin AA, Sathar J, Musa Z, Bakri R, dkk.
Management of transfusion dependent thalassaemia. Malaysia:Ministry of Health
Malaysia; 2009.h.1-84.
17. Skordis N. Endocrine investigation and follow up in thalassemia: times for
specific guimLines. Thalassemia reports. 2011;1:1-16.
18. Sanctis V, Urso, Scialpi, Mangiagli . Endocrine complications in ß-thalassemia
major. Dalam: Maggio A, Hoffbrand AV, penyunting. Clinical aspects and
therapy of haemoglobinopathies. Italy: Proprieta letteraria riservata; 2004.h.293310.
19. Faranoush M, Rahiminejad MS, karamizadeh Z, Ghorbani R, Owji SM. Zinc
supplementation effect linear growth in transfusion dependent ß thalassemia.
IJBC. 2008;1:29-32.
20. Prabhu R, Prabhu V, Prabhu RS. Kelebihan besi in beta thalassemia –a revew. J
Biosci Tech. 2009;1;20-31.
21. Barton JC, Edwards CQ, Phatak PD, Britton RS, Bacon BR. Handbook of iron
overload. Edisi ke-1. New York: Cambridge university Press; 2010.h.233-41.
32
22. Mehvar A, Azarkeivan A, Faranoush M, Mehvar N, Saberinedjhad J, Ghorbani R.
Endocrinophaties with ransfution dependent betha thalassemia. Pediatr
Hem
Onc. 2008; 25:187-94.
23. Shamshirzas AA, Bekheirnia MR, Kamgar M, Pourzahedgilani N, Bouzari N,
Habibzadeh M, dkk. Metabolic and endocrinologic complications in betathalassemia major: a multicenter study in Taheran. BMC Endocrine Disorders.
2003; 3:1-6.
24. Khan FUR, Khan MH, Ayub T, Shah SH. Frekuency of complications in beta
thalassemia major in D.I. Khan. Biomedica. 2007; 23:31-3.
25. Soliman AT, Khalafallah H, Ashour R. Growth and factors affecting it in
thalassemia major. Hemoglobin. 2009; 33:116-26.
26. Low LCK. Growth of children with ß-thalassemia major. Indian J Ped. 2005;
72:159-63.
27. Paulev PE, Calleja GZ. Other hormones and disorders. Dalam : Paulev PE,
Calleja GZ, penyunting. New human fisiology. Edisi ke-2. Copenhagen Denmark.
Elsevier; 2010.h.251-3.
28. Karamifar H, Amirhakimi GH. Linier growth deficiency in ß-thalassemia patiens:
is it growth hormone dependent? IJMS. 2002; 27:47-50.
29. Fica S, Albu A, Vladareanu F, Barbu C, Bunghez R, Nitu L, dkk. Endocrine
disorders in ß-thalassemia major: cross sectional data. Act Endocr. 2005; 1:20112.
30. Roth C, Perkum A, Bartz M, Jarry H, Eber S, Lakomek M. Short stature and
failure of pubertal development in thalassemia major; evidence for hypothalamic
neurosecretory disfuncion of growth hormone secretion and defective pituitary
gonadotropin secretion. Eur J pediatr. 1997; 156:777-83.
31. Vogiatzi MA, Macklin EA, Tractenberg FL, fung EB, Cheung AM, vichinscy E.
Differences in the prevalence of growth, endocrine and vitamin D abnormalities
among the various thalassemia syndromes in North America. British J of
Haematology. 2009; 146:546-56.
33
32. Reiter EO, D’Ercole AJ. Disorders of anterior pituitary gland, hypothalamus and
growth. Dalam: Rudolf AM, Hotcler MK, Lister G, Siegel NJ, penyunting.
Rudolf’s Pediatric. Edisi ke-23. California: McGraw-Hill; 2003: h.2002.
33. Rindang C, batubara JL, Amalia P, Satari H. Some aspects of thyroid dysfunction
in thalassemia major patients with severe iron chelathing. Paediatr indones. 2011;
51:67-72.
34. Eshragi P, Tamaddoni A, Zarifi K, Mohammadhasani A, Aminzadeh M. Thyroid
function in major thalassemia patients: is it related to height and chelation
therapy? Casp J Inern Med. 2011; 2:189-93.
35. Angelucci E, Barosi G, Camaschella C, Cappelini DM, Cazzola , Galanello R.
Italian society of hematology practice guidelines for the management of kelebihan
besi in thalassemia major and related disorders. Haematologica. 2008; 93(5):74152.
36. Sayani F, Warner M, Wu J, Rieger DW, Humphreys K, Odame I. GuimLines for
the clinical care of patient with thalassemia in Canada. Thalassemia foundation of
Canada.Toronto. 2009:15-38.
37. Nabavizadeh SH, Anushiravani A, Haghbin S. Evaluation of growth parameters
in patients with thalassemia major. Hematology. 2007; 12(5):445-7.
38. Ware HM, Kwiatkowski JL. Evaluation and treatment of transfusional iron
overload in children. Pediatr Clin N Am. 2013;1393-1406.
39. Au WY, Li CF, Fang JP, Chen GF, Sun X, Li CG, dkk. Assesment of iron
overload in very young children with limited thalassemia care resources in South
China. Hemoglobin. 2014; 38(2):119-26.
40. Theil EC. Ferritin: at the crossroads of iron and oxygen metabolism. Blood. 1999;
94:3205-311.
41. Belhoul KM, Bakir ML, Saned MS, Kadhim AM, Musallam KM, Taher AT.
Serum ferritin levels and endocrinopathy in medically treated patients with β
thalassemia major. Ann Hematol. 2012; 91:1107-14.
34